Featured in News Medical, Sept 21, 2015
We’re excited by the possibilities that DeepBind can open up for clinical and R&D work around the world. We and others have used DeepBind to identify mutations that disrupt protein binding within the context of disease.
Deep Genomics has an aggressive science and technology roadmap for building a computational system that links together many components that account for different cellular processes.
Think about the Google search engine, but for human mutations. Our first product, SPIDEX, is just one part of that system. In fact, SPIDEX already relies on a simple system that predicts where proteins will bind. We will replace that system with DeepBind and produce SPIDEX data that is much more accurate. All of these components interact and improving one of them boosts the performance of the others. That’s also how deep learning works in general.